- Home
- ARVN vs TNDM Comparison
ARVN vs TNDM Comparison
Compare ARVN & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- TNDM
- Stock Information
- Founded
- ARVN 2015
- TNDM 2006
- Country
- ARVN United States
- TNDM United States
- Employees
- ARVN N/A
- TNDM N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- TNDM Medical/Dental Instruments
- Sector
- ARVN Health Care
- TNDM Health Care
- Exchange
- ARVN Nasdaq
- TNDM Nasdaq
- Market Cap
- ARVN 1.7B
- TNDM 1.9B
- IPO Year
- ARVN 2018
- TNDM 2013
- Fundamental
- Price
- ARVN $25.11
- TNDM $30.74
- Analyst Decision
- ARVN Strong Buy
- TNDM Buy
- Analyst Count
- ARVN 13
- TNDM 16
- Target Price
- ARVN $61.08
- TNDM $52.50
- AVG Volume (30 Days)
- ARVN 718.1K
- TNDM 1.7M
- Earning Date
- ARVN 10-30-2024
- TNDM 11-06-2024
- Dividend Yield
- ARVN N/A
- TNDM N/A
- EPS Growth
- ARVN N/A
- TNDM N/A
- EPS
- ARVN N/A
- TNDM N/A
- Revenue
- ARVN $161,100,000.00
- TNDM $854,351,000.00
- Revenue This Year
- ARVN $237.44
- TNDM $23.61
- Revenue Next Year
- ARVN N/A
- TNDM $10.79
- P/E Ratio
- ARVN N/A
- TNDM N/A
- Revenue Growth
- ARVN 1.07
- TNDM 10.75
- 52 Week Low
- ARVN $21.17
- TNDM $18.45
- 52 Week High
- ARVN $53.08
- TNDM $53.69
- Technical
- Relative Strength Index (RSI)
- ARVN 48.81
- TNDM 44.41
- Support Level
- ARVN $21.17
- TNDM $27.40
- Resistance Level
- ARVN $28.70
- TNDM $29.27
- Average True Range (ATR)
- ARVN 1.72
- TNDM 2.07
- MACD
- ARVN -0.41
- TNDM 0.18
- Stochastic Oscillator
- ARVN 51.44
- TNDM 42.99
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.